{"id":"41b54fa42242","type":"article","url":"https://hartvaat.nl/2024/08/27/stop-semaglutide-vermindert-epicardiaal-vetweefsel-bij-type-2-diabetes/","title":"STOP: semaglutide vermindert epicardiaal vetweefsel bij type 2 diabetes","title_en":"Effect of Semaglutide on Epicardial Adipose Tissue in Type 2 Diabetes: Insights From the STOP (Semaglutide Treatment effect On coronary atherosclerosis Progression) Randomized Trial.","category":"preventie","category_label":"Preventie","professions":["cardioloog","internist"],"tags":["diabetes-en-hart","diabetes-type-1","diabetes-type-2","ezetimibe","figaro-dkd","select-trial","semaglutide","soul-trial","stride-trial"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.05.065","source_url":"https://doi.org/10.1016/j.jacc.2024.05.065","authors":["Venkat Sanjay Manubolu","Suvasini Lakshmanan","April Kinninger","Khadije Ahmad","Shriraj Susarla","Hoon J Seok","Sajad Hamal","Suraj Dahal","Sion K Roy","Matthew J Budoff"],"significance":6,"published":"2024-08-27","source_date":"2024-08-27","image":"","kennis":["https://hartvaat.nl/kennis/preventie/preventie-bij-diabetes/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"The STOP trial showed that semaglutide significantly reduces epicardial adipose tissue in patients with type 2 diabetes, providing mechanistic insight into how GLP-1 agonists may protect the heart through pericardial fat reduction.","created":"2026-07-03T10:31:06Z","updated":"2026-07-03T13:30:09Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"De STOP-trial toonde dat semaglutide het epicardiaal vetweefsel significant vermindert bij type 2 diabetes. Dit mechanistisch inzicht verklaart deels de cardiale voordelen van GLP-1-agonisten.","abstract_original":""}